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Abstract. Cancer stem cells (CSCs) exhibit self-replication, 
self-differentiation, drug resistance and immune evasion 
activities. In recent years CSCs have become increasingly 
important for the treatment of malignant tumors. CSCs express 
specific markers, including cluster of differentiation (CD)44, 
CD44 variant 9 (CD44v9), ATP‑binding cassette sub‑family G 
member 2 (ABCG2), CD24, B lymphoma Mo‑MLV insertion 
region 1 homolog (BMI‑1) and aldehyde dehydrogenase 1 
(ALDH1). However, the prognostic value of their expression 
in patients with oral squamous cell carcinoma (OSCC) are 
not well known. The present study evaluated these markers 
in stage I and II patients with OSCC and examined the asso-
ciation between T classification, histological differentiation, 
classification of invasion mode, lymph node metastasis and 
disease‑free survival rate. Tissue specimens were obtained 
from 70 patients with stage I or II OSCC following either 
surgery or biopsy. Immunohistochemistry was performed 
and positive staining was defiend as 10% positive cells. CD44 
and CD44v9 expressions were strongly detected in all OSCC 
tissues compared with normal epithelial cells. A total of 22 
(31.4%) cases expressed ABCG2 and there was a significant 
association between ABCG2 expression and invasion. A total 
of 41 cases (59.0%) expressed CD24 and there was a significant 
association between CD24 expression and invasion. A total of 
33 cases (47.1%) expressed BMI‑1 and there was a significant 
association between BMI‑1 expression and the disease‑free 
survival rate. A total of 18 cases (25.7%) expressed ALDH1. 
Although there was no association between ALDH1 expres-
sion and T classification, there were significant associations 
between ALDH1 expression and histological differentiation, 
invasion mode, metastasis and the disease-free survival rate. 
Multivariate analysis revealed that ALDH1 expression was 
the only prognostic factor for disease-free survival rate. The 
results of the present study suggest that the positivity of 
ALDH1 detected in patients with OSCC correlates with the 
number of cells undergoing epithelial mesenchymal transition 
and metastasis. These findings indicated that the expression of 
ALDH1 may be an effective prognostic marker indicating the 
survival of patients with stage I and II OSCC.
Introduction
Cancer stem cells (CSCs) are functionally defined by their 
extensive self‑renewal capacity. CSC confers increased radio‑ 
and chemoresistance in tumors, resulting in tumor recurrence 
and metastatic spread. Therefore, identification of the regulators 
that control the tumorigenic potential of CSCs might provide 
new therapeutic strategies against CSCs to improve cancer 
treatment. The CSC theory suggests that only a few cancer 
cells with a capacity for high tumorigenicity, self‑renewal, and 
differentiation are responsible for the maintenance and growth 
of tumors. Similar to normal tissue stem cells, CSCs can also 
exist within a supportive niche (1).
Oral squamous cell carcinoma (OSCC) patients in stage I 
and II are mainly treated by surgery and almost all patients 
show good prognosis, with a 5‑year disease free survival rate 
of early stage OSCC patients over 90%. However, approxi-
mately 10% of these early stage OSCC patients showed poor 
prognosis (2) and some cases have shown cervical lymph 
node metastasis and distant metastasis, with poor outcome. 
Currently, there are no prognostic markers for these stage I and 
II OSCC patients who show poor prognosis.
Cluster of differentiation (CD)44 is a cell surface 
transmembrane glycoprotein encoded by the CD44 gene, 
which consists of 20 exons. The standard isoform of CD44 
is encoded by exons 1‑5 and exons 16‑20, and other CD44 
variant (CD44v) protein isoforms are generated by alternative 
splicing with variable exons (3). CD44 functions in various 
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biological processes, such as cell adhesion, cell migra-
tion, and cancer metastasis. More recently, CD44 has been 
recognized as a CSC marker in several types of cancers (3). 
However, as CD44 is ubiquitously expressed in many cell 
types, its usefulness as a CSC marker may be limited. 
Furthermore, conflicting data in the field implicate the 
importance of CD44 in both tumor suppression and progres-
sion, and these discrepancies have been largely attributed to 
the expression of alternatively spliced variants. Among the 
variants, CD44 variant 9 (CD44v9) may contribute to cancer 
survival in harsh environments, such as high reactive oxygen 
species‑generated conditions from chemotherapy and/or 
radiotherapy (4-6).
ATP‑binding cassette sub‑family G member 2 (ABCG2) 
is a member of the ATP‑binding cassette transporter protein 
superfamily that produces multiple drug-resistant cancers (7) 
and is a molecular determinant for maintaining the side 
population phenotype in stem cells. This phenotype has been 
isolated from several primary tumors and cancer cell lines, 
including those of the lung, esophagus, nasopharynx, and oral 
cavity (8-10). Furthermore, ABCG2 expression has been found 
in solid tumors of hepatocellular, lung, pancreas, and head and 
neck squamous carcinomas (HNSCC) (8-10). ABCG2 plays a 
critical role in the maintenance of the stem cell phenotype and 
multidrug resistance of cancer cells (7). ABCG2 also regulates 
the pattern of cell division in non-small cell lung cancer cell 
lines (9). A recent study suggested that the ABCG2‑positive 
side population cells with the ability to exclude Hoechst 33342 
and the possession of cancer stem‑like properties may play an 
important role in oral carcinogenesis (9). Increasing evidence 
suggests ABCG2 is a marker in CSC and plays a central role in 
tumorigenesis (8-10).
CD24 is a mucin‑like cell surface protein that is expressed 
in cells of the hematopoietic system, in neuronal tissues, and 
in certain epithelial cells such as keratinocytes (11,12). Several 
studies have investigated CD24 expression in various malig-
nant tissues; B cell lymphoma, lung, pancreatic, colorectal, 
breast, and prostate cancer (13-15). Although its physiologic 
functions are not fully elucidated, it seems to be involved in the 
regulation of tumor proliferation and adhesion. In cancer cells, 
the function of CD24 as a ligand for P‑selection may be impor-
tant for the metastatic potential of the tumors by facilitating 
interactions with endothelial cells. Previous studies showed 
that elevation of CD24 expression in various malignant tumors 
is associated with prognosis (12-15).
B‑cell specific Moloney leukemia virus insert site 1 
(BMI‑1) is an essential constituent of polycomb repressive 
complex 1, a key epigenetic regulator. BMI‑1 controls the cell 
cycle and the self‑renewal of tissue stem cells by regulating 
chromatin and histone structure, and has been implicated in 
maintaining the self‑renewal of neural, hematopoietic, and 
intestinal stem cells. Elevated Bmi‑1 expression was demon-
strated to be associated with dysplastic cell transformation 
during oral carcinogenesis and to be required for cancer cell 
replication and survival (16-18).
Aldehyde dehydrogenase 1 (ALDH1) contributes to the 
oxidation of retinol acid in early stem cell differentiation 
and also correlates with the number of cells undergoing 
epithelial-mesenchymal transition, a process that is considered 
a key for the formation of metastasis (19,20). Several studies 
proposed ALDH1 as a putative marker for the identification 
and isolation of CSCs in many kinds of cancers including 
HNSCC (19,21,22). Little is known regarding the biology or 
behavior of CD44, CD44V9, ABCG2, CD24, BMI‑1, ALDH1 
of stage I and II OSCC. We would choose those CSC marker 
among many reports considered important for survival rates 
including esophageal, lung, gastric, colorectal, and head and 
neck cancer (1-19,21,22). And the significance of expression of 
those markers in stage I and II OSCC remains to be determined. 
In this study, we evaluated the association between expression 
of CSC markers and clinicopathological features of stage I 
and II OSCC patients and determined the potential correlation 
between CSC marker expression with clinical factors and prog-
nosis. The aim of the present study was to clarify the prognostic 
factors for stage I and II OSCC patients focused on the expres-
sion of CSC markers. Because we need to find the prognostic 
factor in order to improve the poor outcome of approximately 
10% of early stage OCC patients.
Materials and methods
Patients. Oral cancer tissues were obtained from 70 OSCC 
patients from Tokushima University Hospital at biopsy or surgery. 
Sixty eight cases were used biopsy samples except surgery 
samples of two cases. All patients were treated by surgery. Tumor 
size and clinicopathological stage of OSCC were classified 
according to the TNM staging system (2011). This study was 
approved by the Tokushima University Human Investigations 
Committee Febuary 2016. The Yamamoto‑Kohama (YK) 
classification, which is a modified version of the classification 
of Jakobsson et al (23) and Willen et al (24), was used for 
pathological grade of tumor invasion (25). This classification 
has five grades (1, 2, 3, 4C and 4D) and focuses on the shape of 
tumor cell aggregation at the invasion front.
Immunohistochemistry: Samples were fixed in neutral 
10% formalin and embedded in paraffin after resection. 
Sections (5 µm‑thick) were cut and transferred on slides; 
sections were deparaffinized in xylene and dehydrated in 
graded ethanol. Endogenous peroxidase activity was blocked 
by 1% hydrogen peroxide, and microwave antigen retrieval 
was carried out in a microwave oven. Immunostaining was 
performed using an avidin-biotin peroxidase enzyme complex 
(ABC kit; Vector Laboratories, Burlingame, CA, USA). The 
sections were incubated with monoclonal rabbit anti‑human 
CD44 (clone EPR1013Y: dilution 1:100; Abcam, Cambridge, 
UK), monoclonal rat anti‑human CD44v9 (LKG‑M001: dilu-
tion 1:2,000; Funakoshi, Tokyo, Japan), monoclonal mouse 
anti‑human ABCG2 (clone BXP‑21: dilution 1:100; Abcam), 
monoclonal mouse anti‑human CD24 (clone 8.B.76: dilu-
tion 1:50; Abcam), monoclonal mouse anti‑human Bmi‑1 
(clone 1.T.21: dilution 1:100; Abcam), and monoclonal rabbit 
anti‑human ALDH1 (clone EP1933Y: dilution 1:100; Abcam) 
antibodies overnight at 4˚C, and then subsequently placed 
in secondary anti‑rabbit antibody followed by avidin‑biotin 
complex reagent. The sections were finally incubated in the 
substrate 3,3'diaminobenzidine (0.05%) and 0.1% hydrogen 
peroxide for 8 min. The intensity of immunohistochemical 
staining was graded as negative and positive; expressions of 
CSC markers were considered positive when more than 10% 
of all tumor cells were stained. The grade of staining intensity 
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in case of different biomarkers were not taken into consider-
ation in this study.
Statistical analysis. Statistical analysis was performed by 
Kruskal‑Wallis test, Mann‑Whitney U test between expres-
sions of CSC markers and clinicopathological factors. Survival 
analysis was calculated using the Kaplan‑Meier Method and 
compared using the log‑rank test. Cox hazard regression 
model was used for the multivariate analysis. The results 
were quantified using hazard ratio (HR) with 95% confidence 
interval (95% CI). P<0.05 was considered to indicate a statisti-
cally significant difference.
Results
The expression of CD44, CD44v9, ABCG2, CD24, BMI‑1, and 
ALDH1 in OSCC with stage I and II. This study examined the 
expression of a panel of CSC markers in oral cancer tissues 
from 70 OSCC patients. The clinicopathological data of all 
patients are summarized in Table I. CD44 and CD44v9 protein 
expressions were detected in all OSCC tissues and were 
observed in the majority of tumor cells, as shown in Fig. 1 and 
Table II. CD44 and CD44v9 proteins were expressed in basal 
cell layer of normal oral epithelium and in more than 50% of 
the cells in epithelial dysplasia (data not shown). CD44 and 
CD44V9 proteins were localized to the plasma membrane 
and cytoplasm in cancer cells, and tended to exhibit intense 
irregular and disorganized staining patterns.
The rates of ABCG2, CD24, BMI‑1, and ALDH1 positive 
expression in OSCC patients were 31.4, 59.0, 47.1 and 25.7%, 
respectively (Table II). Representative staining images of 
ABCG2, CD24, BMI‑1, and ALDH1 proteins are presented 
in Fig. 2. ABCG2, CD24, BMI‑1, and ALDH1 proteins were 
expressed in the plasma membrane and cytoplasm. ABCG2, 
CD24, and ALDH1 proteins were mainly localized in the 
invasive front. The well‑differentiated cells forming keratin 
pearls tended to show expression of CD24 and BMI‑1 proteins. 
ALDH1‑positive cells were scattered and were notably absent 
in keratin pearls.
Correlation of CSC marker expressions and clinicopatho‑
logic characteristics. We next examined the correlation of 
CSC marker expressions with clinicopathologic features. 
Although ABCG2 expression was not associated with tumor 
size (Table III), histological differentiation, or lymph node 
metastasis, its expression was significantly associated with clas-
sification of invasion mode (YK classification) in OSCC. CD24 
expression was not associated with tumor size, histological 
Table II. Expression rate of CSC marker.
 No. of positive expression
Marker patients/total patients Percentage
CD44 70/70 100
CD44V9 70/70 100
ABCG2 22/70 31.4
CD24 41/70 59.0
BMI‑1 33/70 47.1
ALDH1 18/70 25.7
CD, cluster of differentiation; OSCC, oral squamous cell carcinoma; 
BMI‑1, B‑cell‑specific Moloney murine leukemia virus insertion 
site 1; ALDH1, aldehyde dehydrogenase 1; CSC, cancer stem cell.
Table I. Clinicopathological characteristics of the patients.
Characteristic Group No. of patients
Sex Male 34
 Female 36
Age (years) Median 68
 Range 35‑97
Primary site Tongue 38
 Oral floor 5
 Upper gingiva 5
 Lower gingiva 16
 Buccal mucosa 6
T classification T1 17
 T2 53
Histological type Well‑differentiated 35
 Moderately differentiated 30
 Poorly differentiated 3
YK classification YK1 5
 YK2 24
 YK3 30
 YK4C 6
 YK4D 3
N status N (+) 14
 N (-) 56
N status, occult cervical lymph node metastasis.
Figure 1. Representative figures of immunohistochemical staining for CD44 
and CD44V9 in the oral mucosa of normal and OSCC tissues. The arrows 
show the basal cell layer. Scale bar, 100 µm. CD, cluster of differentiation; 
OSCC, oral squamous cell carcinoma.
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differentiation, or lymph node metastasis (Table IV). However, 
there was an association between CD24 expression and inva-
sion mode (YK classification). BMI‑1 expression was not 
related with tumor size, histological differentiation, invasion 
mode (YK classification), or lymph node metastasis (Table V). 
There was significant association between ALDH1 expression 
and histological differentiation, invasion mode or lymph node 
metastasis (Table VI).
Survival analysis. We further determined the effects of the 
CSC marker expression in stage I and II OSCC patients on 
survival rate (Fig. 3). The data for overall survival are almost 
same of the data for disease free survival, because only one 
patients was died at other disease other than OSCC. So we 
could not show the data for overall survival. The expressions of 
ABCG2 or CD24 did not show an association with disease‑free 
survival rate. Patients with BMI‑1 expression showed better 
prognosis, and those who lacked BMI‑1 expression showed 
worse prognosis. ALDH1 expression was significantly 
associated with worse prognosis. Multivariate analysis showed 
that ALDH1 expression was the only prognostic factor against 
disease‑free survival rate (HR, 15.82, 95% CI, 1.08‑231.48, 
P=0.04; Table VII).
Discussion
This study clearly demonstrated that there was significant 
association between ALDH1 expression and histological 
differentiation or invasion mode; ABCG2 expression and 
invasion mode; and CD24 expression and invasion mode in 
stage I and II OSCC patients. In addition, the expression of 
ALDH1 and lack of BMI‑1 expression were significantly asso-
ciated with survival in stage I and II OSCC patients.
We determined the expression of CD44 and CD44v9 in 
the oral mucosa and cancer tissues in 70 stage I and II OSCC 
patients. CD44 and CD44v9 expressions were almost in basal 
layer of normal epithelium and were abundantly expressed 
in most tumor cells. A previous study showed that CD44 
Table III. Statistical correlation of ABCG2 expression and clinicopathological features.
Clinicopathological feature Group ABCG2 (+) ABCG2 (‑) P‑value
T classification T1  6 11 0.71
 T2 16 37 
Histological type Well‑differentiated 12 23 
 Moderately differentiated   8 22 0.80
 Poorly differentiated   1   2 
YK classification YK 1  1   4 
(invasion mode) YK 2 12 12 
 YK 3   3 27 0.04
 YK 4C   3   1 
 YK 4D   2   1 
N status N (+)   7   7 0.10
 N (-) 15 41 
N status, occult cervical lymph node metastasis. ABCG2, ATP‑binding cassette sub‑family G member 2.
Figure 2. Representative figures of immunohistochemical positive and negative staining for ABCG, CD24, BMI‑1, and ALDH1 in OSCC tissues. The arrows 
show the keratin pearls. Scale bar, 100 µm. CD, cluster of differentiation; OSCC, oral squamous cell carcinoma; BMI‑1, B‑cell‑specific Moloney murine 
leukemia virus insertion site 1; ALDH1, aldehyde dehydrogenase 1; ABCG2, ATP‑binding cassette sub‑family G member 2.
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expression was detected in 0.1‑41.7% HNSCC cases (26). 
Sato et al found that increased expression of CD44v9 was 
significantly associated with poorer clinical outcome in 
OSCC (27). These findings are not in agreement with the 
results of this study showing that CD44 and CD44v9 were 
abundantly expressed in OSCC. Many reports investigated 
the CD44 expression rate (50~80%) and relationship between 
CD44s expression and clinicopathological factors (28,29). 
However, the results of these studies have been conflicting. 
Mack and Gires showed that the possibilities for these discrep-
ancies may be due to different antibodies used, different 
cut‑offs or different technologies used, i.e. flow cytometry (30). 
Clay et al recently suggested that it was unlikely that CD44+ 
cells were a pure population of CSCs, and highlighted the need 
for its evaluation in combination with another marker (31). This 
study showed that CD44 could not be an important biomarker 
for stage I and II OSCC.
ABCG2 expression was observed in 31.4% of OSCC patients 
in this study, and our data indicates that ABCG2 expression is 
related with invasion mode and is not associated with tumor 
size, differentiation, metastasis, and survival rate. However, 
there were few reports associated with ABCG2 expression 
and cancer cell invasion. On the other hand, it has been shown 
that ABCG2 expression was associated with malignant trans-
formation of oral leukoplakia (OL), oral lichen planus (OLP), 
or oral erythroplakia (OE) (17,32,33). ABCG2 expression 
was observed in 36 of 103 patients with untransformed OL 
and 22 of 32 patients with malignant transformed OL (32). 
Additionally, ABCG2 expression was detected in 21 and 35% 
untransformed OLP and OE patients, respectively, and upon 
malignant transformation, expression rates markedly increased 
to 69 and 88%, respectively (17,33). Although additional experi-
ments are needed to determine whether ABCG2‑positive cells 
are CSCs in oral potentially malignant disorders, these patterns 
Table V. Statistical correlation of BMI‑1 expression and clinicopathological features.
Clinicopathalogical feature Group BMI‑1 (+) BMI‑1 (‑) P‑value
T classification T1  6 11 0.26
 T2 27 26 
Histological type Well‑differentiated 17 18 
 Moderately differentiated 15 15 0.25
 Poorly differentiated   0   3
YK classification YK 1   3  2 
(invasion mode) YK 2 12 12 
 YK 3 14 16 0.55
 YK 4C   2   2 
 YK 4D   0   3
N status N (+)   4 10 0.12
 N (‑) 29 27 
N status, occult cervical lymph node metastasis. BMI‑1, B‑cell‑specific Moloney murine leukemia virus insertion site 1.
Table IV. Statistical correlation of CD24 expression and clinicopathological features.
Clinicopathological feature Group CD24 (+) CD24 (‑) P‑value
T classification T1 12   5 0.25
 T2 29 24 
Histological type Well‑differentiated 24 11 
 Moderately differentiated 15 15 0.21
 Poorly differentiated   1   2 
YK classification YK 1   5   0 
(invasion mode) YK 2 17   7 
 YK 3 12 18 0.03
 YK 4C   3  1 
 YK 4D   1  2 
N status N (+)   9  5 0.60
 N (-) 32 24 
N status, occult cervical lymph node metastasis. CD, cluster of differentiation.
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of ABCG2 expression may reveal its potential as an early 
detection biomarker in precancerous lesions.
CD24 expressions seemed to be implicated in tumor cell 
proliferation, cell-cell interactions, adhesion, and decreased 
E-cadherin expression (34,35). The relationship between CD24 
expression and YK classification of OSCC observed in this 
study might be caused by the decreased E-cadherin expression 
induced through CD24 overexpression. In breast tumors, CD24 
positive cancer cells can be spread more rapidly (36). CD24 
is also considered a potential target for treatment, as previous 
studies showed that CD24‑specific antibodies can inhibit 
the growth of human colorectal and pancreatic cancer cell 
lines (19,34). These authors had suggested that the shift from 
the membranous CD24 localization to the cytoplasm found in 
well‑differentiated tumors could reflect the transition of epithe-
lial cells to a more invasive phenotype (19,34). However, our 
study did not reveal any significant associations between CD24 
Table VII. Cox regression analysis of CSC marker expression 
and disease free survival.
Factor HR (95% CI) P‑value
Age 0.99 (0.91‑1.08) 0.79
Primary site 0.71 (0.27‑1.85) 0.48
Histological type 0.85 (0.22‑3.34) 0.82
YK classification 3.09 (0.80‑12.03) 0.10
ABCG2 0.56 (0.04‑7.51) 0.67
CD24 0.83 (0.09‑7.57) 0.87
BMI‑1 1.85 (0.13‑25.71) 0.21
ALDH1 15.82 (1.08‑231.48) 0.04
HR, harzard ratio; CI, confidence interval; CD, cluster of differentia-
tion; OSCC, oral squamous cell carcinoma; BMI‑1, B‑cell‑specific 
Moloney murine leukemia virus insertion site 1; ALDH1, aldehyde 
dehydrogenase 1; CSC, cancer stem cell.
Table VI. Statistical correlation of ALDH1 expression and clinicopathological features.
Clinicopathalogical feature Group ALDH1 (+) ALDH1 (‑) P‑value
T classification T1  4 13 0.81
 T2 14 39
Histological type Well‑differentiated   7 28 
 Moderately differentiated   8 22 0.01
 Poorly differentiated   3   0
YK classification YK 1   0   5 
(invasion mode) YK 2   4 20 
 YK 3   9 21 0.04
 YK 4C   3   1 
 YK 4D   2   1
N status N (+)   7   7 0.02
 N (-) 11 45 
N status, occult cervical lymph node metastasis. ALDH1, aldehyde dehydrogenase 1.
Figure 3. Disease‑free survival curves according to AGCG2, CD24, BMI‑1 
and ALDH1 expression. The P‑values were determined by log‑rank test. 
CD, cluster of differentiation; OSCC, oral squamous cell carcinoma; BMI‑1, 
B‑cell‑specific Moloney murine leukemia virus insertion site 1; ALDH1, alde-
hyde dehydrogenase 1; ABCG2, ATP‑binding cassette sub‑family G member 2.
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expression and prognosis or other clinicopathologic features, and 
our results are consistent with other studies in OSCC (12,32).
BMI‑1 expression was not associated with tumor size, 
differentiation, invasion mode, or lymph node metastasis in 
this study. High BMI‑1 overexpression was connected to poor 
prognosis in nasopharyngeal cancer, breast cancer and hepato-
cellular carcinoma (16,18). In this study, BMI‑1 expression in 
the OSCC patients led to better prognosis, but lack of BMI‑1 
expression was related with worse prognosis caused by distant 
metastasis. The reason was thought that the Bmi‑1 expression 
would be related with distant metastasis of OSCC in this study. 
Several studies have shown that high BMI‑1 expression was 
associated with poor prognosis (16,18). However, Pietersen et al 
also reported a correlation between high expression of BMI‑1 
and better outcome in OSCC patients (26). These discrepancies 
may be due to the different types of epithelium in the popula-
tion groups, the type of cancers, the population ethnicities, and 
differences in the underlying molecular mechanisms.
The present results show that ALDH1 was significantly 
associated with histological differentiation, invasion mode 
and lymph node metastasis. Moreover, multivariate analysis 
showed that ALDH1 expression was the only prognostic factor 
for disease‑free survival rate. Overexpression of ALDH1 leads 
to increased cell proliferation and, notably, to increased resis-
tance to chemotherapeutic agents (32). Several studies have 
reported an association between ALDH1‑positive tumors and 
poor clinical prognosis in breast, lung, pancreatic, and prostate 
cancer (37). In this study, ALDH1 expression was observed 
in 25.7% of OSCC patients, which is similar as the ALDH1 
expression rate compared with other cancers (37-39). We also 
found that increased ALDH1 expression correlated with poor 
disease‑free survival of OSCC patients. However, contrasting 
results have also been reported. For instance, Chang et al 
reported that ALDH1 expression correlated with favorable 
prognosis in a group of ovarian cancer patients, which included 
266 serous ovarian cancer patients and 176 non-serous ovarian 
cancer patients (38). In addition, Dimou et al reported that 
non‑small cell lung cancer patients with high expression of 
ALDH1 had longer survival and lower recurrence rates (39). 
Thus, more prospective studies are needed to draw a definite 
conclusion. CSCs have major phenotype and functional hetero-
geneities, which may help distinguish them from cancer cells 
and may be of potential benefit in the development of anticancer 
therapies to improve clinical outcomes. Therefore, the present 
study supports the idea that ALDH1 could be a CSC marker, 
because of the significant correlation between ALDH1‑positive 
OSCC patients and common clinical parameters, such as 
histological differentiation, invasion mode (YK classification), 
metastasis, and survival rate. The present findings suggested 
that ALDH1 positively in OSCC were likely to correlate with 
the number of cells undergoing epithelial mesenchymal transi-
tion and a process for the formation of metastasis.
We evaluated 68 biopsy samples and 2 surgery samples. 
However, biopsy tissues might not reflect the whole part of 
tumors. The present findings of this study might not be the 
results of CSC marker expression of the whole tumors. We 
should need to investigate the confirmation of this study.
In conclusion, our study indicated that the expression of 
ALDH1 could be an effective CSC marker to indicate the 
outcome of early stage OSCC patients.
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